187 related articles for article (PubMed ID: 38179880)
1. Gilbert's syndrome leads to elevated bilirubin after initiation of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis.
Patel N; Ansar M; Pham A; Thomsen K; McKinzie CJ; Polineni D; Esther CR; Brown RF
Pediatr Pulmonol; 2024 Apr; 59(4):863-866. PubMed ID: 38179880
[TBL] [Abstract][Full Text] [Related]
2. Case Series: Hyperbilirubinemia under elexacaftor/tezacaftor/ivacaftor in the presence of Gilbert's syndrome.
Weitzel J; Welsner M; Taube C; Ballmann M; Sutharsan S
BMC Pulm Med; 2024 Jul; 24(1):307. PubMed ID: 38956524
[TBL] [Abstract][Full Text] [Related]
3. Perceived burden of respiratory physiotherapy in people with cystic fibrosis taking elexacaftor-tezacaftor-ivacaftor combination: a 1-year observational study.
Blardone C; Gambazza S; Mariani A; Galgani R; Brivio A; Nobili RM; Rizza C; Tutino AL; Gramegna A; Daccò V; Contarini M; Blasi F; Laquintana D
Ther Adv Respir Dis; 2024; 18():17534666241235054. PubMed ID: 38554035
[TBL] [Abstract][Full Text] [Related]
4. Determining the minimal clinically important difference for the questionnaire of olfactory disorders in people with cystic fibrosis and factors associated with improvement after highly effective modulator therapy.
Miller JE; Taylor-Cousar JL; Overdevest JB; Khatiwada A; Mace JC; Alt JA; Bodner TE; Chowdhury NI; DiMango EA; Eshaghian PH; Getz AE; Gudis DA; Han EJ; Hwang PH; Keating CL; Khanwalkar A; Kimple AJ; Lee JT; Li D; Markarian K; Norris M; Nayak JV; Owens C; Patel ZM; Poch K; Schlosser RJ; Smith KA; Smith TL; Soler ZM; Suh JD; Tervo JP; Turner GA; Wang MB; Saavedra MT; Beswick DM
Int Forum Allergy Rhinol; 2024 Jun; 14(6):1079-1087. PubMed ID: 38145393
[TBL] [Abstract][Full Text] [Related]
5. Organic Synthesis and Current Understanding of the Mechanisms of CFTR Modulator Drugs Ivacaftor, Tezacaftor, and Elexacaftor.
Ferreira FC; Buarque CD; Lopes-Pacheco M
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398574
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal profiling of the intestinal microbiome in children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor.
Reasoner SA; Bernard R; Waalkes A; Penewit K; Lewis J; Sokolow AG; Brown RF; Edwards KM; Salipante SJ; Hadjifrangiskou M; Nicholson MR
mBio; 2024 Feb; 15(2):e0193523. PubMed ID: 38275294
[TBL] [Abstract][Full Text] [Related]
7. Fetal drug exposure after maternally administered CFTR modulators Elexacaftor/Tezacaftor/Ivacaftor in a rat model.
Li D; Zhu Y; Donnelley M; Parsons D; Habgood MD; Schneider-Futschik EK
Biomed Pharmacother; 2024 Feb; 171():116155. PubMed ID: 38232663
[TBL] [Abstract][Full Text] [Related]
8. Persistence and evolution of
Armbruster CR; Hilliam YK; Zemke AC; Atteih S; Marshall CW; Moore J; Koirala J; Krainz L; Gaston JR; Lee SE; Cooper VS; Bomberger JM
mBio; 2024 May; 15(5):e0051924. PubMed ID: 38564694
[TBL] [Abstract][Full Text] [Related]
9. Multisystemic Effects of Elexacaftor-Tezacaftor-Ivacaftor in Adults with Cystic Fibrosis and Advanced Lung Disease.
Burgel PR; Paillasseur JL; Durieu I; Reynaud-Gaubert M; Hamidfar R; Murris-Espin M; Danner-Boucher I; Chiron R; Leroy S; Douvry B; Grenet D; Mely L; Ramel S; Montcouquiol S; Burnet E; Ouaalaya EH; Sogni P; Da Silva J; Martin C;
Ann Am Thorac Soc; 2024 Jul; 21(7):1053-1064. PubMed ID: 38579175
[No Abstract] [Full Text] [Related]
10. Impact of elexacaftor/tezacaftor/ivacaftor on lipid and fat-soluble vitamin levels and association with body mass index.
Patel T; McBennett K; Sankararaman S; Schindler T; Sundaram K; Minich NM; Malay S; Kutney K
Pediatr Pulmonol; 2024 Mar; 59(3):734-742. PubMed ID: 38179878
[TBL] [Abstract][Full Text] [Related]
11. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare
Burgel PR; Sermet-Gaudelus I; Girodon E; Kanaan R; Le Bihan J; Remus N; Ravoninjatovo B; Grenet D; Porzio M; Houdouin V; Le Clainche-Viala L; Durieu I; Nove-Josserand R; Languepin J; Coltey B; Guillaumot A; Audousset C; Chiron R; Weiss L; Fajac I; Da Silva J; Martin C;
Eur Respir J; 2024 Jan; 63(1):. PubMed ID: 38242629
[No Abstract] [Full Text] [Related]
12. Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
Dooney M; Saba T
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423592
[No Abstract] [Full Text] [Related]
13. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
Burgel PR
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423591
[No Abstract] [Full Text] [Related]
14. PREFUL MRI for Monitoring Perfusion and Ventilation Changes after Elexacaftor-Tezacaftor-Ivacaftor Therapy for Cystic Fibrosis: A Feasibility Study.
Dohna M; Voskrebenzev A; Klimeš F; Kaireit TF; Glandorf J; Pallenberg ST; Ringshausen FC; Hansen G; Renz DM; Wacker F; Dittrich AM; Vogel-Claussen J
Radiol Cardiothorac Imaging; 2024 Apr; 6(2):e230104. PubMed ID: 38573129
[TBL] [Abstract][Full Text] [Related]
15. Impact of elexacaftor/tezacaftor/ivacaftor on respiratory colonization in an adult cystic fibrosis clinic.
Szabo MM; Foushee SE; McPheeters CM; O'Hagan AR; Ramirez AM; O'Reilly EA
Am J Med Sci; 2024 May; 367(5):337-342. PubMed ID: 38336262
[TBL] [Abstract][Full Text] [Related]
16. Nontuberculous mycobacterial pulmonary infections in the era of elexacaftor-tezacaftor-ivacaftor.
Mingora CM; Caverly LJ
J Cyst Fibros; 2024 Jan; 23(1):3-4. PubMed ID: 38307802
[No Abstract] [Full Text] [Related]
17. Elexacaftor/tezacaftor/ivacaftor in liver or kidney transplanted people with cystic fibrosis using tacrolimus, a drug-drug interaction study.
van der Meer R; Wilms EB; Eggermont MN; Paalvast HM; van Luin M; van Rossen RCJM; Heijerman HGM
J Cyst Fibros; 2024 May; 23(3):549-553. PubMed ID: 38290918
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Elexacaftor-Tezacaftor-Ivacaftor on chronic rhinosinusitis in cystic fibrosis.
Di Gioia S; Lucca F; Venditto L; Sandri G; Tommasi N; Cipolli M; Molteni G
Am J Otolaryngol; 2024; 45(3):104236. PubMed ID: 38417261
[TBL] [Abstract][Full Text] [Related]
19. Use of elexacaftor+tezacaftor+ivacaftor in individuals with cystic fibrosis and at least one F508del allele: a systematic review and meta-analysis.
Silva Filho LVRFD; Athanazio RA; Tonon CR; Ferreira JC; Tanni SE
J Bras Pneumol; 2024; 49(6):e20230187. PubMed ID: 38198345
[TBL] [Abstract][Full Text] [Related]
20. Elexacaftor/tezacaftor/ivacaftor influences body composition in adults with cystic fibrosis: a fully automated CT-based analysis.
Westhölter D; Haubold J; Welsner M; Salhöfer L; Wienker J; Sutharsan S; Straßburg S; Taube C; Umutlu L; Schaarschmidt BM; Koitka S; Zensen S; Forsting M; Nensa F; Hosch R; Opitz M
Sci Rep; 2024 Apr; 14(1):9465. PubMed ID: 38658613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
